What does Avalo Therapeutics, Inc. do?
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory…
What is Avalo Therapeutics, Inc.'s P/E and P/B ratio?
Avalo Therapeutics, Inc. has a P/E ratio of -1.7 and a P/B ratio of 0.89.
What is Avalo Therapeutics, Inc.'s debt-to-equity ratio?
Avalo Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Avalo Therapeutics, Inc. owe compared with what it owns?
Avalo Therapeutics, Inc. owes $0.09 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Avalo Therapeutics, Inc.'s Positivity rank?
Avalo Therapeutics, Inc. is ranked #1,955 of 6,774 companies globally and #518 of 4,000 in United States on PositoAI, with a Positivity Score of 22,085.
Does Avalo Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Avalo Therapeutics, Inc..
Where can I read the latest news about Avalo Therapeutics, Inc.?
Recent headlines about Avalo Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Avalo Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Avalo Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.